Nicole Longo Nicole is director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Recent Posts
Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R&D
By Nicole Longo | November 16, 2020
Today, America leads the world in medical innovation because of our unique research ecosystem, but that wasn’t always the case. A new paper from NDP Analytics, “Will US Leadership in...
Read More
PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients
By Nicole Longo | November 2, 2020
In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander, PhRMA has outlined a number of commonsense ways...
Read More
340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients
By Nicole Longo | October 23, 2020
The 340B program – a safety-net federal drug program meant to help vulnerable Americans – has become dominated by many large hospitals and for-profit corporations with no clear evidence they are...
Read More
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
By Nicole Longo | October 13, 2020
In comments recently submitted to the administration, PhRMA raised concerns with a number of changes included in the Centers for Medicare & Medicaid Services (CMS) Medicaid proposed rule. Today,...
Read More
Growth in 340B program has not translated to improvements for patients
By Nicole Longo | October 5, 2020
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? That’s the most important question policymakers should be asking in any discussion about the 340B program....
Read More
Recent administration actions undermine patient assistance programs
By Nicole Longo | September 16, 2020
While all eyes and ears are focused on COVID-19 and beating this pandemic, the administration has pursued harmful policy changes that we can’t let slip under the radar. In two back-to-back...
Read More
Executive order threatens R&D when we need it most to fight COVID-19
By Nicole Longo | July 30, 2020
In case you missed it, President Trump recently signed executive orders that would implement sweeping changes to the biopharmaceutical industry. While his intention may have been to help Americans...
Read More
PhRMA submits comments to CMS on Medicaid proposed rule
By Nicole Longo | July 21, 2020
In response to the Centers for Medicare and Medicaid Services’ (CMS) proposed rule regarding changes to Medicaid, PhRMA provided feedback on how the changes included would have widespread impacts...
Read More
By the numbers: A look at the sourcing of API used in medicines consumed in the United States
By Nicole Longo | July 16, 2020
There has been a lot of focus of late on where active pharmaceutical ingredients (APIs) for medicines are manufactured. While some may claim we are reliant on other countries, putting us at risk...
Read More
Stakeholders raise concerns with proposed drastic changes to the pharmaceutical supply chain
By Nicole Longo | June 11, 2020
As we work to combat the current global pandemic, it is especially critical to maintain the stability of our global manufacturing supply chain. Unfortunately, recent policy proposals that would...
Read More
Medicare Monday (100)
340B Spotlight (45)
Cost & Consequence (0)
